Bendamustine, bortezomib and rituximab produces durable complete remissions in patients with previously untreated, low grade lymphoma

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-2141|180|3|365-373

ISSN： 0007-1048

Source： BRITISH JOURNAL OF HAEMATOLOGY, Vol.180, Iss.3, 2018-02, pp. : 365-373

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A phase II study of bortezomib added to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with previously untreated indolent non‐Hodgkin's lymphoma

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 171, Iss. 4, 2015-11 ,pp. : 539-546

John Wiley & Sons Inc

Access to resources Recommend Favorite

Pentostatin, cyclophosphamide and rituximab for previously untreated advanced stage, low‐grade B‐cell lymphomas

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 169, Iss. 6, 2015-06 ,pp. : 814-823

John Wiley & Sons Inc

Access to resources Recommend Favorite

Antibody Therapy with Rituximab for Patients with Low-Grade Non-Hodgkin’s Lymphoma

By  

Oncology Research and Treatment, Vol. 22, Iss. 3, 1999-07 ,pp. : 184-190

Karger

Access to resources Recommend Favorite

A phase 2 trial of extended induction epratuzumab and rituximab for previously untreated follicular lymphoma: CALGB 50701

By  

CANCER, Vol. 119, Iss. 21, 2013-11 ,pp. : 3797-3804

John Wiley & Sons Inc

Access to resources Recommend Favorite

Bortezomib with Thalidomide plus Dexamethasone Compared with Thalidomide plus Doxorubicin and Dexamethasone as Induction Therapy in Previously Untreated Multiple Myeloma Patients

By  

Acta Haematologica, Vol. 129, Iss. 1, 2012-10 ,pp. : 35-39

Karger

Access to resources Recommend Favorite